Kyntra Bio (KYNB) vs Universe Pharmaceuticals (UPC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Kyntra Bio (KYNB) has outperformed Universe Pharmaceuticals (UPC) over the past year, losing 47.7% versus a loss of 55.8%. Over five years, KYNB leads with a -97.8% price change compared with -99.9% for UPC. Kyntra Bio is the larger company by market cap ($24.1 million vs $21.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KYNB | UPC |
|---|---|---|
| Share price | $5.96 | $4.18 |
| Market cap | $24.13M | $21.00M |
| 1-day change | -1.32% | -5.00% |
| YTD return | -32.12% | +9.71% |
| 1-year return | -47.72% | -55.81% |
| 5-year return | -97.84% | -99.95% |
| EPS (TTM) | $-7.64 | $-1.38 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $11.65 | $17.96 |
| 52-week low | $5.62 | $2.00 |
| Distance from 52-week high | -48.84% | -76.73% |
| Analyst consensus | none | — |
| Avg. price target upside | +565.60% | — |
| Average volume | 18.29K | 788.87K |
| Shares outstanding | 4.05M | 5.01M |
| Employees | 34 | 216 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Kyntra Bio
KYNB stock →Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 34 employees
About Universe Pharmaceuticals
UPC stock →Universe Pharmaceuticals INC, through its subsidiaries, engages in the manufacturing, marketing, distribution, and sales of traditional Chinese medicine derivative products in China. The company offers products for the treatment and relief of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications.
Health Care · Biotechnology: Pharmaceutical Preparations · 216 employees
KYNB vs UPC FAQ
Which is bigger, Kyntra Bio or Universe Pharmaceuticals?
Kyntra Bio (KYNB) is larger, with a market capitalization of $24.13M compared with $21.00M for Universe Pharmaceuticals (UPC).
Which stock has performed better over the past year, KYNB or UPC?
KYNB returned -47.72% over the past 12 months, compared with -55.81% for UPC (price return, excluding dividends). Past performance does not predict future results.
Are Kyntra Bio and Universe Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.